Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine for Sedation in Palliative COVID-19
NCT04350086Phase 4Withdrawn
- Sponsor
- CHU de Limoges
- Start
- Apr 2020
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of dexmedetomidine in coronavirus disease 2019 (COVID-19), respiratory failure, sponsored by CHU de Limoges. Planned start Apr 2020; status: withdrawn.
02
Drugs
dexmedetomidine
03
Conditions
coronavirus disease 2019 (COVID-19)respiratory failure
Beyond the preview
Go deeper on NCT04350086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04350086.